Overview

A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy

Status:
Recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the safety of a study drug called Rucaparib, administered in combination with the type of radiation therapy that is usually given to women with your form of breast cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborator:

Clovis Oncology, Inc.

Treatments:

Rucaparib